Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-07-13

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT00039208

Locations: 🇫🇷
Hopital Saint-Louis, Paris, France
🇫🇷
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
🇫🇷
Centre Hospital Regional Universitaire de Limoges, Limoges, France

and more 17 locations

S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: irinotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-14

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 61

Registration Number: NCT00012363

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States

and more 93 locations

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

Phase 1

Completed

Conditions: Esophageal Cancer
Gastric Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005638

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 3

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-03-08

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT00020501

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Primary CNS Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Primary Central Nervous System Non-Hodgkin Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma

Interventions: Drug: irinotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00003970

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Phase 2

Completed

Conditions: Alveolar Childhood Rhabdomyosarcoma
Embryonal Childhood Rhabdomyosarcoma
Embryonal-botryoid Childhood Rhabdomyosarcoma
Previously Treated Childhood Rhabdomyosarcoma
Recurrent Childhood Rhabdomyosarcoma

Interventions: Drug: vincristine sulfate
Drug: irinotecan hydrochloride
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: etoposide
Drug: tirapazamine
Biological: filgrastim
Biological: sargramostim
Other: pharmacological study
Other: pharmacogenomic studies
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 150

Registration Number: NCT00025363

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer

Phase 2

Terminated

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: gefitinib
Drug: leucovorin calcium
Drug: fluorouracil

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00052585

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-18

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00040807

Locations: 🇺🇸
Penrose Cancer Center, Colorado Springs, Colorado, United States
🇺🇸
Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

and more 40 locations

UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2010-08-09

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 30

Registration Number: NCT00047242

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Registration Number: NCT00027833

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Scranton Hematology-Oncology, Scranton, Pennsylvania, United States

and more 10 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy